Table of Contents
Treatment & Management
- What is the standard treatment regimen for leprosy?
The WHO recommends multidrug therapy (MDT) as the global standard of care. Paucibacillary leprosy is treated with dapsone and rifampicin for six months. Multibacillary leprosy requires dapsone, rifampicin, and clofazimine taken together for twelve months. All MDT medications are provided free of charge to patients worldwide through WHO supply programs.
- How are lepra reactions treated?
Type 1 reversal reactions are managed with corticosteroids — typically prednisolone — to rapidly reduce nerve inflammation and prevent irreversible damage. Type 2 ENL reactions are treated with thalidomide in male patients or corticosteroids in female patients, with clofazimine added for recurrent or chronic ENL. Critically, multidrug therapy is continued unchanged throughout the management of any reaction.
- Can nerve damage from leprosy be reversed?
Nerve damage detected and treated early — particularly within the first six months of a reaction — is potentially reversible with prompt and adequate corticosteroid therapy. However, established axonal degeneration causing muscle wasting, foot drop, or claw hand deformity is permanent, which is precisely why early diagnosis and aggressive reaction management are non-negotiable.
- What is the role of physiotherapy in leprosy management?
Physiotherapy plays a central role in preventing contractures, maintaining residual muscle strength, and rehabilitating existing deformities. Equally important is patient education in self-care for insensate limbs — patients are trained to inspect their hands, feet, and eyes daily for unnoticed injuries, burns, or pressure sores, which are the leading cause of secondary disability in leprosy.
- Is there a vaccine for leprosy?
BCG vaccination offers partial and variable protection against leprosy, with efficacy estimates ranging from 40% to 80% depending on geographic region and study design. Newer vaccine candidates using killed M. leprae or recombinant mycobacterial antigens are under active research, but no dedicated, universally approved leprosy vaccine is currently available for routine deployment.
Epidemiology & Misconceptions
- Is leprosy still prevalent today?
Leprosy remains a significant global health concern, with over 200,000 new cases reported annually. India, Brazil, and Indonesia together account for the vast majority of cases worldwide. Despite the WHO declaring leprosy “eliminated as a public health problem” in 2000 — meaning fewer than one case per 10,000 population — the disease has never been eradicated and continues to cause new disability every year.
- Is leprosy highly contagious?
Contrary to centuries of stigma and fear, leprosy is one of the least contagious infectious diseases known. Over 95% of the global population has natural genetic immunity to M. leprae. Transmission requires prolonged, repeated close contact with an untreated multibacillary patient, most likely through respiratory droplets — not through casual touch, sharing utensils, or brief social interaction.
- Can animals carry and transmit leprosy?
The nine-banded armadillo is the only known wild animal reservoir of M. leprae, harboring the organism in large numbers due to its naturally low body temperature. Zoonotic transmission to humans has been documented in the southern United States, particularly in Louisiana and Texas, in individuals who handle, hunt, or consume armadillo meat.
- Why is leprosy still associated with social stigma?
Millennia of religious condemnation, cultural fear, and misunderstanding of transmission have embedded leprosy stigma deeply into societies across the world. The visible disfigurement of advanced disease reinforces rejection even today. This stigma causes patients to hide symptoms and avoid healthcare, directly delaying diagnosis and allowing preventable disability to accumulate — a social tragedy that anti-stigma education campaigns continue to combat.
- What is pure neuritic leprosy?
Pure neuritic leprosy is a rare and diagnostically challenging form of the disease in which peripheral nerve thickening and neuropathy develop without any visible skin lesions whatsoever. It accounts for up to 10% of all leprosy cases in South Asia and requires nerve biopsy to confirm the diagnosis, since neither skin smear nor clinical skin examination yields useful findings.
- What are the Grade 2 disabilities in leprosy?
WHO Grade 2 disability in leprosy refers to visible, permanent deformities resulting from nerve damage. These include claw hand from ulnar nerve palsy, foot drop from peroneal nerve damage, lagophthalmos (inability to fully close the eye) from facial nerve involvement, corneal ulceration from exposure keratopathy, and plantar ulcers from insensate feet. Grade 2 disabilities are the primary driver of social exclusion and economic marginalization in affected communities.
- What does the future of leprosy research look like?
The next era of leprosy control is being shaped by several converging advances. Whole-genome sequencing of M. leprae strains is revealing transmission chains and drug resistance patterns. Serological tests using the PGL-I antigen are enabling earlier, subclinical detection. Post-exposure prophylaxis with a single dose of rifampicin for close contacts is reducing the incidence of new cases in trials. And next-generation vaccine candidates are moving through early-phase studies, raising cautious hope that eradication may one day move from ambition to reality.
Medical Disclaimer:
The information provided on this website is for general educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
